How Does China’s Patent Linkage System Work for Foreign Pharma Companies?

China’s patent linkage system—officially the 药品专利链接制度 (Drug Patent Linkage System, yàopǐn zhuānlì liànjiē zhìdù)—is a regulatory mechanism that connects generic drug marketing approval with patent status, and since its launch on June 1, 2021, it has fundamentally changed how foreign pharmaceutical companies protect their exclusivity in China’s ¥2.5 trillion (USD 350 billion) drug market. Before this system, generics could receive market approval while patent disputes remained unresolved, creating a “first-mover” risk for innovators. Today, the mechanism creates a structured, court-backed pause—a 9-month statutory stay—that gives patent holders time to defend their intellectual property before a generic competitor can launch.

For foreign pharma, the system replaces reactive litigation with a proactive registration-and-challenge framework. Since implementation, the China National Drug Administration (NMPA, 国家药品监督管理局, guójiā yàopǐn jiāndū guǎnlǐ jú) and the China National Intellectual Property Administration (CNIPA, 国家知识产权局, guójiā zhīshì chǎnquán jú) have processed over 40 patent linkage disputes, with 70% of rulings favoring patent holders in the first two years. Understanding how this system works—and where its gaps remain—is now essential for any foreign firm launching or defending an innovative drug in China.

What Is Patent Linkage and Why Was It Introduced in China?

Patent linkage is the legal process that prevents a national drug regulator (in China, the NMPA) from approving a generic copy of an innovator drug while the innovator’s patent is still in force—unless the generic applicant successfully challenges the patent’s validity or shows non-infringement. China’s version was codified through the Fourth Amendment to the Patent Law (effective June 1, 2021) and the Implementing Regulations for the Drug Patent Linkage System (effective July 4, 2021).

The system was introduced for two primary reasons. First, China wanted to align its pharmaceutical IP regime with international standards, particularly the US Hatch-Waxman Act, to attract foreign R&D investment. Second, it aimed to resolve a persistent mismatch: NMPA had no authority to consider patent status during drug approval, so generics could enter the market years before patent litigation concluded. The linkage system closes that gap by requiring generic applicants to make a patent declaration (专利声明, zhuānlì shēngmíng) at the time of filing, directly triggering a legal mechanism that delays approval until the patent dispute is resolved.

The system is administered jointly by NMPA (approval authority) and CNIPA (patent expertise), with the Beijing Intellectual Property Court and the Supreme People’s Court providing final adjudication. This dual-regulator structure is a key difference from the US system, where only the courts handle patent challenges.

How Does the Patent Linkage Process Work Step by Step?

The process follows a structured timeline with clear triggers, deadlines, and consequences. Below is a step-by-step breakdown:

1. Patent Registration: The innovator (patent holder) registers relevant patents on the China Listed Drug Patent Information Registration Platform (中国上市药品专利信息登记平台, zhōngguó shàngshì yàopǐn zhuānlì xìnxī dēngjì píngtái). Only certain patent types qualify: drug compound patents, composition patents, and use patents for approved indications. The deadline for registration is 30 days after drug marketing approval.
2. Generic Application and Declaration: A generic applicant (仿制药申请者, fǎngzhì yào shēnqǐng zhě) files an abbreviated new drug application (ANDA) with NMPA and must submit a patent declaration stating one of four categories:
   • Type 1: No relevant patent exists on the platform.
   • Type 2: The relevant patent has expired.
   • Type 3: The patent holder has committed to a license or the generic applicant agrees to wait for patent expiry.
   • Type 4: The relevant patent is invalid or will not be infringed by the generic product.
3. Notification Trigger: If the generic applicant files a Type 4 declaration, they must notify the patent holder within 20 days. The patent holder then has 45 days to decide whether to file a patent infringement lawsuit at the Beijing Intellectual Property Court or request an administrative ruling from CNIPA.
4. Statutory Stay (9 Months): If the patent holder files a lawsuit or administrative request within the 45-day window, NMPA imposes a 9-month statutory stay on the generic application’s approval. During this period, the court or CNIPA must issue a first-instance ruling. If no ruling is issued within 9 months, NMPA may proceed with the generic’s approval.
5. Final Resolution: If the court finds the patent valid and infringed, the generic cannot be approved until the patent expires (or a settlement is reached). If the generic applicant prevails (patent invalid or not infringed), NMPA proceeds with approval.

The table below summarizes the key milestones and timelines:

This timeline gives foreign pharma a 9-month window to argue their case before any generic can launch—a significant improvement over the pre-2021 system, where generics could gain approval and begin stocking pharmacy shelves while patent litigation was still pending.

What Are the Key Differences Between China’s System and the US Hatch-Waxman System?

China’s patent linkage system was modeled on the US Hatch-Waxman Act, but it has critical differences that foreign pharma must understand to avoid strategic missteps.

Scope of registrable patents. In the US, innovators can list any patent that claims the drug or its approved use, including formulation and method-of-use patents. China’s platform is narrower: it only accepts drug compound, composition, and use patents—and only if they are directly related to the approved indication. Process patents and polymorph patents are excluded. This means a foreign pharma company that relies on a polymorph patent (e.g., a crystalline form of the API) cannot register it on the platform and cannot invoke the linkage stay against a generic that claims non-infringement of that patent.

Administrative vs. judicial pathway. In the US, patent challenges are exclusively handled by federal district courts, with a mandatory 30-month stay if the innovator sues within 45 days. In China, the patent holder has a choice: file a lawsuit in the Beijing Intellectual Property Court or request an administrative invalidation or non-infringement ruling from CNIPA. The CNIPA route is faster (typically 6–8 months) and cheaper, but CNIPA decisions can be appealed to the courts, adding 12–18 months. The court route takes longer but provides a final, appealable judgment that cannot be easily overturned.

No automatic 180-day generic exclusivity. Under US law, the first generic to successfully challenge a patent receives 180 days of market exclusivity—a powerful incentive to file Type IV (Paragraph IV) certifications. China does not offer such an exclusivity incentive for first filers. This means Chinese generic applicants have a lower financial motivation to challenge patents early, which can delay the entry of generics even when patents are weak. For foreign pharma, this reduces the frequency of Type 4 declarations, but it also means that when a challenge does come, the generic applicant is likely to be a well-funded, aggressive player.

No “reverse payment” precedent. In the US, patent linkage settlements often involve “reverse payment” agreements where the innovator pays the generic to delay market entry. China has no legal framework or established case law for such settlements, and the antitrust authorities (SAMR) have signaled they view large reverse payments as potentially monopolistic. Foreign pharma must therefore pursue patent linkage cases to a court or CNIPA ruling rather than relying on settlement as a primary strategy.

How Should Foreign Pharma Companies Adapt Their China Patent Strategy?

For foreign pharma, the patent linkage system is not merely a legal mechanism—it is a strategic tool that must be integrated into the overall China market entry plan. Here are the key adaptations:

Register early and register comprehensively. The most common failure among foreign pharma in the first two years of the system was late or incomplete patent registration. Because only registered patents can invoke the 9-month stay, any unregistered patent is effectively unenforceable against generic entry under the linkage framework. Companies must create an internal checklist that identifies all eligible patents within 30 days of NMPA approval and upload them to the platform. This includes confirming that the patent’s claims match the approved indication exactly—any mismatch can lead to platform rejection.

Monitor Type 4 declarations actively. The system requires the generic applicant to notify the patent holder, but in practice, notifications can be delayed or lost. Foreign pharma should assign a dedicated IP monitoring team to check the NMPA public database monthly for any ANDA filings on their registered drugs. If a Type 4 declaration appears, the 45-day clock starts ticking immediately—delays in filing a lawsuit or CNIPA request forfeit the stay.

Prepare for parallel litigation. A patent linkage case before the Beijing IP Court or CNIPA is not the only legal battle a foreign pharma company may face. Generic applicants sometimes file separate invalidation requests against the patent at CNIPA while the linkage case is ongoing, or they may launch a marketing approval application for a different dosage form that does not trigger linkage. Foreign pharma should have a multi-front legal strategy that covers the linkage case, a parallel invalidation defense, and—if necessary—a separate infringement action outside the linkage framework.

Below is a decision framework that helps foreign pharma choose their response to a Type 4 declaration:

Decision Framework for Type 4 Declaration Response:

If your patent is listed on the platform and the generic’s product clearly falls within the patent’s claims, choose the Beijing IP Court lawsuit route—it offers the strongest legal basis for a preliminary injunction and the most authoritative ruling. If your patent has a known vulnerability (e.g., a weak prior art record) and you need a faster, lower-cost outcome, choose the CNIPA administrative route—it typically resolves in 6–8 months and avoids the cost of a full trial. If the generic applicant is a major Chinese firm with a strong legal team, choose both simultaneously—file the court lawsuit to secure the stay and file a CNIPA request to pressure the generic on two fronts.

3 Pitfalls for Foreign Pharma Under China’s Patent Linkage System

NEXT STEPS

For foreign pharma companies navigating China’s patent linkage system, the right response depends on where you are in your product lifecycle. Here are three actionable next steps:

1. Audit your China patent portfolio now: Review all patents protecting your approved and pipeline drugs. Identify which are eligible for the platform and which are not. File any missing registrations immediately. For detailed guidance, read: How to Register Patents on China’s Drug Patent Information Platform.
2. Build a Type 4 declaration monitoring system: Set up monthly checks of the NMPA database for ANDA filings on your registered drugs. Create a 45-day response protocol that includes a pre-approved template for filing a lawsuit or CNIPA request. For a step-by-step monitoring guide, see: Monitoring Type 4 Patent Declarations in China.
3. Develop a parallel litigation strategy for non-registrable patents: For drugs protected by patents that cannot be listed on the platform, create a separate enforcement plan that includes CNIPA invalidation defense and, if necessary, a regular patent infringement lawsuit outside the linkage framework. For strategy recommendations, read: Defending Polymorph and Formulation Patents Against Chinese Generics.

— China Gateway 360 —
Remote China market entry support, built around execution.